Safety
The safety of Nobivac® Lyme in dogs 8 weeks or older was confirmed in a 618-dog field study.1
Client-owned dogs were vaccinated subcutaneously with a 1-mL dose of Nobivac® Lyme and boosted with an additional 1-mL dose 21 days later, for a total of 1,236 vaccine administrations. Dogs were monitored for adverse reactions beginning with the first vaccination and continuing through 14 days after the second vaccination.
Subcutaneous administration of Nobivac® Lyme was infrequently associated with pain on injection and had a low incidence of localized reactions. Mild, transient soft tissue swelling, which may occur at the injection site, is a typical response following subcutaneous vaccination with a whole-cell bacterin. Overall, less than 1% of dogs experienced adverse reactions attributable to the vaccine.
- The vaccine was well-tolerated on subcutaneous administration
- Nobivac® Lyme was 99.3% reaction-free
- No dogs were removed from the study
Reference:1. Data on file at Intervet/Schering-Plough Animal Health.
